High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00561314|
Recruitment Status : Completed
First Posted : November 20, 2007
Last Update Posted : August 26, 2013
RATIONALE: Highly focused ultrasound energy may be able to kill tumor cells by heating the tumor without affecting the surrounding tissue.
PURPOSE: This phase II trial is studying the side effects and how well highly focused ultrasound energy works in treating patients with localized prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer Sexual Dysfunction Urinary Incontinence||Other: questionnaire administration Procedure: biopsy Procedure: high-intensity focused ultrasound ablation Procedure: magnetic resonance imaging Procedure: quality-of-life assessment||Phase 2|
- To evaluate feasibility, side effect profile, and patient acceptability of high-intensity focused ultrasound ablation in patients with organ-confined, MRI and histologically proven adenocarcinoma of the prostate.
- To determine the effectiveness of therapy via biopsy, MRI, PSA level and estimated time to PSA nadir, and by recording the need for secondary or adjuvant treatment following therapy.
OUTLINE: A probe is inserted into the rectum. High-intensity focused ultrasound (HIFU) energy using the Sonablate system is delivered to the prostate tissue over approximately 2 hours. Patients are then evaluated over a 12-month period.
Patients undergo multi-sequence MRI within 10-20 days after HIFU to assess the extent and volume of tumor necrosis and again at 6 months to assess for disease recurrence. Blood is collected for PSA levels at baseline and then at 1, 3, 6, 9, and 12 months. Patients also undergo transrectal ultrasound biopsy at 6 months to evaluate disease response.
Patients complete questionnaires at baseline and at 1, 3, 6, 9, and 12 months to evaluate erectile and sexual function, urinary flow and continence, and quality-of-life.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||33 participants|
|Official Title:||An Evaluation of Focal Ablation Therapy Using High-Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||February 2009|
|Actual Study Completion Date :||January 2012|
- Feasibility, patient acceptability and side effect profile of high-intensity focal ultrasound ablation as determined by adverse events
- Patient acceptability, urinary symptoms, and erectile function as assessed by Functional Assessment of Cancer Treatment-Prostate (FACT-P); Item International Index of Erectile Dysfunction (IIEF-15); International Prostate Symptom Score (IPSS); I ...
- Effectiveness of high-intensity focal ultrasound ablation to control prostate cancer as determined by time to PSA nadir, MRI at 10-20 days and again at 6 months, biopsies of treated areas at 6 months, and by recording the need for secondary or adjuva ...
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561314
|Basingstoke and North Hampshire NHS Foundation Trust|
|Basingstoke, England, United Kingdom, RG24 9NA|
|University College of London Hospitals|
|London, England, United Kingdom, WIT 3AA|
|Study Chair:||Mark Emberton, MD, FRCS, MBBS||University College London Hospitals|